Baxter International (BAX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.56
- Estimate
- $0.37
- Surprise
- +52.5%
- Revenue (period 2026-06-30)
- $2.96B
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Baxter International (BAX) beat the $0.37 estimate with adjusted EPS of $0.56 — a large 52.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BAX Sell at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +52.5% surprise compares with a +16.5% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Concentration risk — Supplier: single source suppliers
- Target reached (-3.7% upside)
- Quality below floor (3.7 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $25.22
- Price target
- $29.00
- Stop
- $23.94
- Upside to target
- +15.0%
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
BAX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $12.82B
- P/E (fwd)
- 12.2
- 52-week range
- $15.73–$30.00
- Off 52-week high
- 15.9%
- RSI (14)
- 73
- Volume vs avg
- 0.02×
- Score today
- 5.5/10